Age 0 3 0 3 B-age
> 4 5 4 5 O
55 6 8 6 8 B-lower_bound
years 9 14 9 14 I-lower_bound

Age 0 3 15 18 B-age
younger 4 11 19 26 O
than 12 16 27 31 O
55 17 19 32 34 B-upper_bound
years 20 25 35 40 I-upper_bound

Clinically 0 10 41 51 O
significant 11 22 52 63 O
cerebrovascular 23 38 64 79 B-chronic_disease
disease 39 46 80 87 I-chronic_disease
including 47 56 88 97 O
cortical 57 65 98 106 O
infarct 66 73 107 114 O
, 73 74 114 115 O
strategically 75 88 116 129 O
located 89 96 130 137 O
subcortical 97 108 138 149 O
gray 109 113 150 154 O
matter 114 120 155 161 O
or 121 123 162 164 O
extensive 124 133 165 174 O
white 134 139 175 180 O
matter 140 146 181 187 O
abnormalities 147 160 188 201 O

Have 0 4 202 206 O
Mild 5 9 207 211 B-chronic_disease
Cognitive 10 19 212 221 I-chronic_disease
Impairment 20 30 222 232 I-chronic_disease
( 31 32 233 234 I-chronic_disease
MCI 32 35 234 237 I-chronic_disease
) 35 36 237 238 I-chronic_disease
as 37 39 239 241 O
defined 40 47 242 249 O
under 48 53 250 255 O
diagnosis 54 63 256 265 O
above 64 69 266 271 O

Have 0 4 272 276 O
a 5 6 277 278 O
Body 7 11 279 283 B-bmi
Mass 12 16 284 288 I-bmi
Index 17 22 289 294 I-bmi
( 23 24 295 296 I-bmi
BMI 24 27 296 299 I-bmi
) 27 28 299 300 I-bmi
â‰¥35 29 32 301 304 O

If 0 2 305 307 O
a 3 4 308 309 O
woman 5 10 310 315 B-gender
and 11 14 316 319 O
peri 15 19 320 324 O
- 19 20 324 325 O
menopausal 20 30 325 335 O
and 31 34 336 339 O
unwilling 35 44 340 349 O
to 45 47 350 352 O
maintain 48 56 353 361 O
current 57 64 362 369 O
hormone 65 72 370 377 B-treatment
replacement 73 84 378 389 I-treatment
therapy 85 92 390 397 I-treatment
status 93 99 398 404 O
and 100 103 405 408 O
allowed 104 111 409 416 O
medication 112 122 417 427 B-treatment
usage 123 128 428 433 O
during 129 135 434 440 O
the 136 139 441 444 O
study 140 145 445 450 O

Medications 0 11 451 462 O
with 12 16 463 467 O
significant 17 28 468 479 O
effect 29 35 480 486 O
on 36 38 487 489 O
memory 39 45 490 496 O
such 46 50 497 501 O
as 51 53 502 504 O
anticholinergic 54 69 505 520 B-treatment
( 70 71 521 522 O
diphenhydramine 71 86 522 537 B-treatment
, 86 87 537 538 O
tricyclic 88 97 539 548 B-treatment
antidepressants 98 113 549 564 I-treatment
, 113 114 564 565 O
benztropine 115 126 566 577 B-treatment
) 126 127 577 578 O
; 127 128 578 579 O
sedative 129 137 580 588 B-treatment
hypnotics 138 147 589 598 I-treatment
such 148 152 599 603 O
as 153 155 604 606 O
benzodiazepines 156 171 607 622 B-treatment
; 171 172 622 623 O
narcotics 173 182 624 633 B-treatment
; 182 183 633 634 O
and 184 187 635 638 O
antiparkinsonian 188 204 639 655 O
medications 205 216 656 667 O
will 217 221 668 672 O
all 222 225 673 676 O
be 226 228 677 679 O
excluded 229 237 680 688 O

Scored 0 6 689 695 O
below 7 12 696 701 O
24 13 15 702 704 B-upper_bound
on 16 18 705 707 O
the 19 22 708 711 O
MMSE 23 27 712 716 B-clinical_variable
( 28 29 717 718 O
have 29 33 718 722 O
dementia 34 42 723 731 B-chronic_disease
) 42 43 731 732 O

To 0 2 733 735 O
avoid 3 8 736 741 O
inaccurate 9 19 742 752 O
HDL 20 23 753 756 O
and 24 27 757 760 O
HDL2 28 32 761 765 O
- 32 33 765 766 O
C 33 34 766 767 O
determinations 35 49 768 782 O
or 50 52 783 785 O
avoid 53 58 786 791 O
bias 59 63 792 796 O
from 64 68 797 801 O
familial 69 77 802 810 B-chronic_disease
hypercholesterolemia 78 98 811 831 I-chronic_disease
, 98 99 831 832 O
respectively 100 112 833 845 O
, 112 113 845 846 O
participants 114 126 847 859 O
with 127 131 860 864 O
TG 132 134 865 867 B-clinical_variable
> 135 136 868 869 O
400 136 139 869 872 B-lower_bound
mg 140 142 873 875 I-lower_bound
/ 142 143 875 876 I-lower_bound
dl 143 145 876 878 I-lower_bound
and 146 149 879 882 O
those 150 155 883 888 O
whose 156 161 889 894 O
LDL 162 165 895 898 B-clinical_variable
- 165 166 898 899 I-clinical_variable
C 166 167 899 900 I-clinical_variable
levels 168 174 901 907 I-clinical_variable
> 175 176 908 909 O
95 176 178 909 911 B-lower_bound
% 178 179 911 912 I-lower_bound
or 180 182 913 915 O
HDL 183 186 916 919 B-clinical_variable
levels 187 193 920 926 I-clinical_variable
< 194 195 927 928 O
10 195 197 928 930 B-upper_bound
% 197 198 930 931 I-upper_bound
of 199 201 932 934 O
age 202 205 935 938 B-age
and 206 209 939 942 O
sex 210 213 943 946 O
- 213 214 946 947 O
adjusted 214 222 947 955 O
norms 223 228 956 961 O
will 229 233 962 966 O
be 234 236 967 969 O
excluded 237 245 970 978 O

Unstable 0 8 979 987 O
medical 9 16 988 995 O
conditions 17 27 996 1006 O
indicated 28 37 1007 1016 O
by 38 40 1017 1019 O
starting 41 49 1020 1028 O
new 50 53 1029 1032 O
medications 54 65 1033 1044 O
within 66 72 1045 1051 O
6 73 74 1052 1053 B-upper_bound
weeks 75 80 1054 1059 I-upper_bound
of 81 83 1060 1062 O
enrollment 84 94 1063 1073 O
will 95 99 1074 1078 O
be 100 102 1079 1081 O
disallowed 103 113 1082 1092 O

Willing 0 7 1093 1100 O
to 8 10 1101 1103 O
exercise 11 19 1104 1112 O
for 20 23 1113 1116 O
12 24 26 1117 1119 B-upper_bound
months 27 33 1120 1126 I-upper_bound

include 0 7 1127 1134 O
> 8 9 1135 1136 O
2 9 10 1136 1137 B-lower_bound
mm 11 13 1138 1140 I-lower_bound
ST 14 16 1141 1143 B-treatment
depression 17 27 1144 1154 I-treatment
, 27 28 1154 1155 O
extra 29 34 1156 1161 O
systole 35 42 1162 1169 O
, 42 43 1169 1170 O
chest 44 49 1171 1176 B-chronic_disease
pain 50 54 1177 1181 I-chronic_disease
, 54 55 1181 1182 O
arrhythmias 56 67 1183 1194 B-chronic_disease
, 67 68 1194 1195 O
hypotension 69 80 1196 1207 B-chronic_disease
and 81 84 1208 1211 O
or 85 87 1212 1214 O
dizziness 88 97 1215 1224 O
or 98 100 1225 1227 O
significant 101 112 1228 1239 O
ST 113 115 1240 1242 O
segment 116 123 1243 1250 O
elevation 124 133 1251 1260 O
during 134 140 1261 1267 O
the 141 144 1268 1271 O
treadmill 145 154 1272 1281 O
test 155 159 1282 1286 O

persons 0 7 1287 1294 O
with 8 12 1295 1299 O
neurological 13 25 1300 1312 B-chronic_disease
, 25 26 1312 1313 O
psychiatry 27 37 1314 1324 B-chronic_disease
or 38 40 1325 1327 O
other 41 46 1328 1333 O
clinical 47 55 1334 1342 O
conditions 56 66 1343 1353 O
likely 67 73 1354 1360 O
to 74 76 1361 1363 O
cause 77 82 1364 1369 O
dementia 83 91 1370 1378 B-chronic_disease

